Fact of Medicine
Brand Name: Braftovi
Innovator Brand Name: Braftovi
API: Encorafenib
Packaging: 60/90 Capsules
Strength: 50/75mg
Manufacturer Name: Array BioPharma, Inc.

Get Price


Encorafenib Medication

Braftovi (Encorafenib) is a kinase inhibitor used:

  • together with binimetinib, to treat patients with unresectable/metastatic melanoma with a mutation named BRAF V600E or V600K.
  • together with cetuximab, to treat adult patients with metastatic colorectal cancer (CRC) with a mutation named BRAF V600E, after prior therapy.

Dosage: The recommended dose of Braftovi (Encorafenib) for Melanoma is 450 mg orally taken once daily along with binimetinib. The recommended dose of Encorafenib for CRC is 300 mg orally once daily along with the drug cetuximab. Encorafenib may be administered either with or without food. Do not administer a missed encorafenib dose within 12 hours of the next dose of encorafenib. Do not take an additional dose in case vomiting occurs after encorafenib administration but continue with the next scheduled dose.

Side Effects: Melanoma: The most commonly reported encorafenib side effects along with binimetinib include:

  • Fatigue
  • Nausea
  • Vomiting
  • Abdominal pain
  • Arthralgia

CRC: The most commonly reported side effects for encorafenib, along with cetuximab include:

  • Rash
  • Fatigue
  • Nausea
  • Diarrhea
  • Abdominal pain
  • Decreased appetite
  • Arthralgia
  • Dermatitis acneiform

Warnings and Precautions:

  • Monitor patients with encorafenib 75 mg capsule for signs and symptoms of non-cutaneous malignancies.
  • Patients with encorafenib dosage should be done for ophthalmologic evaluation at regular intervals and for any visual disturbances while on the therapy.
  • Patients should be monitored for the electrolytes prior to and while on the braftovi 50 mg treatment.
  • Monitor patients for malignancies and dermatologic evaluations should be done prior to, while on encorafenib fda label medication, and following interruption of therapy.
  • Findings and mechanism of action of braftovi 75 mg suggest that this drug can cause fetal harm if administered to a pregnant woman.
  • Advise women not to breastfeed while on treatment with encorafenib 50 mg and for 14 days after the final dose.

More info

Storage: Store Braftovi (Encorafenib capsules) below 30°C. Store it in the original package in order to protect from the moisture. Availability in India: The Indian Pharma helps connect buyers with suppliers who can ship the BRAFTOVI at the global level as per the needs of buyer’s. The Indian Pharma provides guarantee of quality as well as delivery for the BRAFTOVI Capsules. Buying Procedure: In order to buy BRAFTOVI, you can contact us at our Toll-free number 1800 889 1064 or on WhatsApp number +919310090915 or an Email to us at: info@theindianpharma.com along with your valid Identity Proof, Legitimate Prescription letter and Medical Reports. Conclusion: Encorafenib (Braftovi), together with cetuximab and binimetinib resulted in significant longer overall survival and a higher RR (Response Rate) in comparison to standard therapy in recipients/patients with metastatic melanoma and metastatic colorectal cancer with the BRAF V600E mutation.


What is Braftovi? Braftovi is a prescription agent used to treat patients with unresectable or metastatic melanoma and metastatic colorectal cancer (CRC). What does Braftovi contain as an active substance? The medication Braftovi specifically contains the active substance Encorafenib. Is Encorafenib an FDA approved drug? Yes, Encorafenib is an FDA approved drug. How much does braftovi cost? The braftovi price usually may vary depending on the wholesaler/pharmacy you visit and of course the brand you choose. What is the best price for Encorafenib? Please contact Toll-free: +91 1800 889 1064|+919310090915 for encorafenib price in India. We take guarantee of quality as well as delivery anywhere in the world as per the buyer’s requirements. Can I get Braftovi (Encorafenib) even if I am not based in India? The Indian Pharma helps patients in accessing or importing Braftovi (Encorafenib), not approved in their home country against the legitimate prescription and in conformity with the all local laws and regulations of their home country.